Blue Cross NCCommercial · Billing Codes · Medical Policy · NC · Oncology, Hematology, Rheumatology +2 moreMedium impact
Medical Criteria Update for April 6, 2022
Act
immediately
Effective date
Apr 6, 2022
Identified
Jun 16, 2026
Summary
Blue Cross NC updated their medical criteria to add five new specialty drugs with associated HCPCS codes (Nexviazyme, Saphnelo, Tezspire, Enjaymo, and Leqvio) and updated the HCPCS code for Evkeeza from a temporary code to permanent code J1305. These changes provide clarity for billing these specialty medications.
Get alerts when payers change rules like this one
We check Blue Cross NC and other payers every day and email you when a change matches your specialty and state.
01Billing team must update drug billing system to use permanent HCPCS code J1305 for Evkeeza instead of temporary codes.
02Add the five new specialty drugs (Nexviazyme, Saphnelo, Tezspire, Enjaymo, Leqvio) with their respective HCPCS codes to the billing system if administering these medications.
03Verify individual drug policies for specific prior authorization requirements.
Codes mentioned
C9085J3490J3590C9086C9399J1305
Original notice
Medical Criteria Update for April 6, 2022
bluecrossnc.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.